AstraZeneca Redefining Cancer Care in Breast Cancer, Leukemia at ASCO

AstraZeneca Redefining Cancer Care in Breast Cancer, Leukemia at ASCO

Source: 
BioSpace
snippet: 

Throughout the past few days, AstraZeneca has been presenting data at the American Society of Clinical Oncology (ASCO) Annual meeting that reaffirms the company’s commitment to redefine cancer care.

In a pre-ASCO panel co-led by The Cancer Support Community, AstraZeneca asked the million-dollar question: Are we ready to talk cure in cancer? While the panelists, which included oncologists, researchers and AstraZeneca executives, didn’t come to a clear conclusion, the company is making headway in at least two indications: post-surgery, high-risk HER2-negative early breast cancer and chronic lymphocytic leukemia (CLL).